Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Robert ZivadinovJennie MedinNasreen KhanJonathan R KornNiels P BergslandMichael G DwyerTanuja ChitnisRobert T NaismithEnrique AlvarezPeter KinkelStanley CohanSamuel F HunterDiego SilvaBianca Weinstock-Guttmannull nullPublished in: Journal of neuroimaging : official journal of the American Society of Neuroimaging (2018)
The study provides real-world evidence that rate of brain atrophy in MS patients with underlying active disease and NEAD in fingolimod treated patients is below the established pathological cutoff for loss of whole brain volume (>-.4%) or expansion of lateral ventricles (> 3.5%).
Keyphrases
- multiple sclerosis
- white matter
- resting state
- end stage renal disease
- newly diagnosed
- ejection fraction
- functional connectivity
- mass spectrometry
- chronic kidney disease
- cerebral ischemia
- prognostic factors
- computed tomography
- minimally invasive
- brain injury
- patient reported outcomes
- patient reported
- diffusion weighted imaging